Literature DB >> 17963772

Ceramide: a common pathway for atherosclerosis?

Jean Bismuth1, Peter Lin, Qizhi Yao, Changyi Chen.   

Abstract

Plasma sphingomyelin concentration is correlated with the development of atherosclerosis. It has been found to exist in significantly higher concentrations in aortic plaque. This appears to have clinical relevance as well as it has been shown to be an independent predictor of coronary artery disease. Ceramide, the backbone of sphingolipids, is the key component which affects atherosclerotic changes through its important second-messenger role. This paper sheds light on some of the current literature supporting the significance of ceramide with respect to its interactions with lipids, inflammatory cytokines, homocysteine and matrix metalloproteinases. Furthermore, the potential therapeutic implications of modulating ceramide concentrations are also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17963772      PMCID: PMC2924671          DOI: 10.1016/j.atherosclerosis.2007.09.018

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  91 in total

1.  Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity?

Authors:  Ira Tabas
Journal:  Circulation       Date:  2004-11-30       Impact factor: 29.690

2.  Letter regarding article by Augé et al., "Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation".

Authors:  Cemil Izgi; Cihan Cevik; Mehmet Ozkan
Journal:  Circulation       Date:  2005-02-01       Impact factor: 29.690

3.  Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation.

Authors:  Shang-Der Chen; Chaur-Jong Hu; Ding-I Yang; Abdullah Nassief; Hong Chen; Kejie Yin; Jan Xu; Chung Y Hsu
Journal:  Ann N Y Acad Sci       Date:  2005-05       Impact factor: 5.691

4.  The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis.

Authors:  Zhiqiang Li; Maria J Basterr; Tiruneh K Hailemariam; Mohammad Reza Hojjati; Shendi Lu; Jin Liu; Ruijie Liu; Hongwen Zhou; Xian-Cheng Jiang
Journal:  Biochim Biophys Acta       Date:  2005-07-15

5.  Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice.

Authors:  Mohammad Reza Hojjati; Zhiqiang Li; Hongwen Zhou; Songshan Tang; Chongmin Huan; Everlyn Ooi; Shendi Lu; Xian-Cheng Jiang
Journal:  J Biol Chem       Date:  2004-12-06       Impact factor: 5.157

6.  Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase.

Authors:  T B Rajavashisth; J K Liao; Z S Galis; S Tripathi; U Laufs; J Tripathi; N N Chai; X P Xu; S Jovinge; P K Shah; P Libby
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

7.  Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice.

Authors:  Tae-Sik Park; Robert L Panek; Mark D Rekhter; Sandra Bak Mueller; Wendy S Rosebury; Andrew Robertson; Jeffrey C Hanselman; Erick Kindt; Reynold Homan; Sotirios K Karathanasis
Journal:  Atherosclerosis       Date:  2006-02-02       Impact factor: 5.162

8.  Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo.

Authors:  R A Memon; N M Bass; A H Moser; J Fuller; R Appel; C Grunfeld; K R Feingold
Journal:  Biochim Biophys Acta       Date:  1999-08-25

9.  Sphingomyelinase causes endothelium-dependent vasorelaxation through endothelial nitric oxide production without cytosolic Ca(2+) elevation.

Authors:  Kimiko Mogami; Hiroko Kishi; Sei Kobayashi
Journal:  FEBS Lett       Date:  2005-01-17       Impact factor: 4.124

10.  Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice.

Authors:  Tae-Sik Park; Robert L Panek; Sandra Bak Mueller; Jeffrey C Hanselman; Wendy S Rosebury; Andrew W Robertson; Erick K Kindt; Reynold Homan; Sotirios K Karathanasis; Mark D Rekhter
Journal:  Circulation       Date:  2004-11-15       Impact factor: 29.690

View more
  61 in total

1.  Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients.

Authors:  Sharda Anroedh; Mika Hilvo; K Martijn Akkerhuis; Dimple Kauhanen; Kaisa Koistinen; Rohit Oemrawsingh; Patrick Serruys; Robert-Jan van Geuns; Eric Boersma; Reijo Laaksonen; Isabella Kardys
Journal:  J Lipid Res       Date:  2018-06-01       Impact factor: 5.922

2.  Breaking through the surface: more to learn about lipids and cardiovascular disease.

Authors:  Justin B Echouffo-Tcheugui; Mohit Jain; Susan Cheng
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

3.  Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin.

Authors:  Ming Tong; Lisa Longato; Teresa Ramirez; Valerie Zabala; Jack R Wands; Suzanne M de la Monte
Journal:  Int J Exp Pathol       Date:  2013-10-29       Impact factor: 1.925

4.  Sphingolipid metabolism regulates development and lifespan in Caenorhabditis elegans.

Authors:  Roy G Cutler; Kenneth W Thompson; Simonetta Camandola; Kendra T Mack; Mark P Mattson
Journal:  Mech Ageing Dev       Date:  2014-11-28       Impact factor: 5.432

5.  Ceramide signaling in the coronary microcirculation: a double-edged sword?

Authors:  Brian R Weil; John M Canty
Journal:  Circ Res       Date:  2014-08-15       Impact factor: 17.367

Review 6.  2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis.

Authors:  Ira Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-12-15       Impact factor: 8.311

7.  Endothelial Nogo-B regulates sphingolipid biosynthesis to promote pathological cardiac hypertrophy during chronic pressure overload.

Authors:  Yi Zhang; Yan Huang; Anna Cantalupo; Paula S Azevedo; Mauro Siragusa; Jacek Bielawski; Frank J Giordano; Annarita Di Lorenzo
Journal:  JCI Insight       Date:  2016-04-21

8.  LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL.

Authors:  M John Chapman; Alexina Orsoni; Ricardo Tan; Natalie A Mellett; Anh Nguyen; Paul Robillard; Philippe Giral; Patrice Thérond; Peter J Meikle
Journal:  J Lipid Res       Date:  2020-04-15       Impact factor: 5.922

Review 9.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

10.  Ceramide signaling in cancer and stem cells.

Authors:  Erhard Bieberich
Journal:  Future Lipidol       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.